Post-earnings recap
Reported
Fri, May 10, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
TG Therapeutics reported a wider-than-expected loss per share, which contributed to a 6.78% drop in stock price. Investors may be concerned about the lack of revenue updates and the cautious tone from management. The absence of guidance could lead to uncertainty about the company's future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.43 | N/A | +9.04% |
| Revenue | N/A | N/A | N/A |
Management expressed caution regarding current market conditions. They reiterated their commitment to advancing their product pipeline despite challenges.
Management highlighted ongoing challenges in the market.
They emphasized the need for continued focus on product development.
There were no specific updates on future revenue expectations.